Alert Data News | Business | Companies | UK | Biotechnology

Xceleron Limited (In Administration)

Mon, 06 Feb 2012 15:47:50 +0000

Xceleron Announces New Investment
Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.

Xceleron Limited (In Administration)

Mon, 06 Feb 2012 15:47:50 +0000

Xceleron Lands $2.4M From Albion Ventures and Solon Ventures
Xceleron, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company's business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012.

Byotrol Plc

Fri, 03 Feb 2012 15:00:11 +0000

New product launched with partner - Contract extended worth £300,000
Byotrol plc, the developer of anti microbial hygiene technologies, and partner Rentokil Initial Plc, have formally launched the UltraProtect range, powered by Byotrol, under a contract announced in July 2011. UltraProtect is a range of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes. In addition, Byotrol has agreed terms for a six month extension of the Joint Development Agreement ('JDA') with their Fortune 150 partner company, for which Byotrol Consumer Products Limited will receive $300,000. Gary Millar is the Chief Executive of Byotrol Plc.

Angel Biotechnology Holdings PLC

Fri, 13 Jan 2012 08:00:02 +0000

Revenue £3m - Loss for year expected - New Commercial Director
Angel Biotechnology, the biopharmaceutical contract manufacturer, has achieved a revenue of £3 million in the 12 months to December 2011. The company expects to make a loss for the year. Contracts have been extended, however no new contracts have been signed due to capacity constraints. Dr Stewart White has been appointed to the newly created post of Commercial Director.

Shire Biopharmaceuticals Holdings Limited

Thu, 15 Dec 2011 15:00:02 +0000

Non-Executive Director retires
Dr Jeffrey Leiden will be stepping down from the Shire Biopharmaceuticals Holdings Limited Board and its Board Committees with effect from January 31, 2012. Dr Leiden has been a non executive director of Shire since January 2007. Matthew Emmens is Shires Chairman.

Genzyme Limited

Fri, 11 Nov 2011 00:00:00 +0000

Cambridge research facility facing closure - 70 job losses expected
The Genzyme European research facility in Cambridge UK, which employs 70 staff, is facing closure as French parent company Sanofi plans major restructuring to concentrate R&D in France, Asia, Germany and the USA. No time frame had yet been determined.

Byotrol Plc

Mon, 07 Nov 2011 11:00:02 +0000

Byotrol Plc - Result of EGM
BYOT - at the General Meeting of shareholders held earlier today, both proposed resolutions were duly passed. Accordingly, the Company confirms that is has completed the placing of 31,709,927 new ordinary shares of 0.25 pence each (the "Ordinary Shares") (the "Placing Shares") and subscription o...

Shire Biopharmaceuticals Holdings Limited

Fri, 28 Oct 2011 15:21:18 +0100

Strong drug sales keep Shire on track
LONDON (Reuters) - Shire Plc , Britain's third-largest drugmaker, reported 24 percent third-quarter revenue growth, helped by robust demand for hyperactivity drugs and its medicines for rare diseases...

Xceleron Limited (In Administration)

Tue, 25 Oct 2011 15:47:50 +0100

Registry of biomedical companies - Xceleron Ltd
Xceleron is a proven Translational Research partner to a range of over 100 pharma-biotech businesses, both private and public, adding value through optimisation of Exploratory Clinical Development programmes.

Angel Biotechnology Holdings PLC

Mon, 17 Oct 2011 15:21:36 +0100

Angel Biotechnology plans to grow in jvc deal
Outsourcing and Services | Contract Manufacturing | Business and Finance | Biotechnology |